NantHealth, Inc. NH
1.35 +1.35
Day range unavailable
52-week range unavailable
- Analysts
- Buy
- Price target
- 4.00 (+196.3%)
- Earnings date
- May 25, 2023
No chart data for this range yet.
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: buy
Buy
Price target (mean) 4.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
May 25, 2023
Expected May 25, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 25, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -1.20 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -1.35 | — | — | — |
| Feb 24, 2022 | Dec 1, 2021 | -1.35 | — | — | — |
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on NH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLSCRIPTS HEALTHCARE SOLUTIONS INC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 6, 2016 | 15,000,000 |
| BLASZYK MICHAEL D | Director | Stock Award(Grant) | Sep 5, 2018 | 148,780 |
| CALHOUN KIRK K | Director | Stock Award(Grant) | Sep 5, 2018 | 148,780 |
| HOLT PAUL ALAN | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 6, 2018 | 64,742 |
| LOUKS RONALD ALLEN | Chief Operating Officer | Sale | Sep 12, 2021 | 225,857 |
| SITRICK MICHAEL S | Director | Stock Award(Grant) | Sep 5, 2018 | 148,780 |